Skip to main content

Table 1 Characteristics of the safety population (N = 331)

From: Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study

Age (years)

50.0 ± 11.5

  < 65

297 (90)

 65–75

25 (7.6)

  ≥ 75

7 (2.1)

 Missing

2 (0.6)

Gender

 Male

305 (92)

 Female

26 (7.9)

Hepatitis B

 

 Yes

296 (89)

 No

6 (1.8)

 Othersa

36 (11)

Portal vein thrombosis

 Yes

98 (30)

 No

190 (57)

 Unknown

43 (13)

Number of liver lesions

 1–3

196 (59)

  > 3

112 (34)

HCC confined to liver, yes

142 (43)

Vascular invasion, yes

74 (22)

Extrahepatic spread, yes

134 (41)

TNM stage

 I or II

60 (18)

 III

129 (39)

 IV

72 (22)

 Missing or unknown

70 (21)

Barcelona Clinic Liver Cancer stage

 A or B

76 (23)

 C or D

222 (67)

 Not evaluable

33 (10)

Child-Pugh class

 A

220 (67)

 B or C

38 (12)

 Not evaluable

73 (22)

Cancer of the Liver Italian Program score

 0

49 (15)

 1

51 (15)

 2

54 (16)

 3

51 (15)

 4–6

46 (14)

Prior surgery

111 (34)

Prior locoregional therapy

 None

89 (27)

 Percutaneous ethanol injection only

2 (0.6)

 Radiofrequency ablation only

16 (4.8)

 Transarterial chemoembolization only

172 (52)

 Concomitantb

50 (15)

 Others

2 (0.6)

  1. Data are presented as mean ± standard deviation or count (percentage). Percentages are presented to 2 significant figs
  2. HCC hepatocellular carcinoma, TNM tumor node metastasis
  3. aOthers include five hepatitis C, five alcohol use, 23 unknown, two other, and one other hepatobiliary disorders/findings
  4. bConcomitant therapy refers to using at least two therapies for loco-regional anti-cancer treatment at baseline